Position in PRGO
as of Jun 30, 2026
· filed Jul 16, 2026
Position Value
$215,208
-$7,475 QoQ
Shares Held
20,713
-0.1% QoQ
Ownership
0.015%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#178
of 334 holders
Holding Since
Sep 2023
12 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in PRGO Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Linden Thomas Advisory Services, LLC holds $9,701,809 across 5 Drug Manufacturers - Specialty & Generic names. PRGO ranks #5 (2.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | KNSA |
Kiniksa Pharmaceuticals International, plc
|
54,803 | $3,504,651 | |
| 2 | NBIX |
Neurocrine Biosciences Inc
|
18,676 | $3,147,653 | |
| 3 | LNTH |
Lantheus Holdings, Inc.
|
19,695 | $2,184,963 | |
| 4 | ELAN |
Elanco Animal Health Inc
|
26,385 | $649,334 | |
| 5 | PRGO |
PERRIGO Co plc
This page
|
20,713 | $215,208 |
All Filings in PRGO
Export CSV
12 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $215,208 | 20,713 | Shares | Sole | 2026-07-16 | |
| 2026-03-31 | $222,683 | 20,734 | Shares | Sole | 2026-04-10 | |
| 2025-12-31 | $270,660 | 19,444 | Shares | Sole | 2026-01-16 | |
| 2025-09-30 | $447,537 | 20,096 | Shares | Sole | 2025-11-06 | |
| 2025-06-30 | $522,803 | 19,566 | Shares | Sole | 2025-07-31 | |
| 2025-03-31 | $552,584 | 19,707 | Shares | Sole | 2025-04-30 | |
| 2024-12-31 | $488,052 | 18,983 | Shares | Sole | 2025-01-21 | |
| 2024-09-30 | $520,272 | 19,835 | Shares | Sole | 2024-10-17 | |
| 2024-06-30 | $512,161 | 19,944 | Shares | Sole | 2024-07-10 | |
| 2024-03-31 | $648,081 | 20,133 | Shares | Sole | 2024-04-30 | |
| 2023-12-31 | $630,760 | 19,601 | Shares | Sole | 2024-02-01 | |
| 2023-09-30 | $637,722 | 19,960 | Shares | Sole | 2023-10-20 | |
| No filing history on record for this holder in this stock. | ||||||